Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$0.11
-0.01 (-5.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $38.3M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$180M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.3%
↓Gross Margin
29.8%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.5%
FCF CAGR
+44.4%
FCF margin
12.9%
FCF / Net income
-3.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $972.0M · net income $-40.7M · FCF $125.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $972.0M | $972.0M | $1.04B | $1.06B | $986.7M |
| Net Income | $-40.7M | $-40.7M | $25.0M | $24.1M | $54.3M |
| EBITDA | $-11.2M | $-11.2M | $69.3M | $69.9M | $125.2M |
| EPS | — | — | 0.01 | 0.01 | 0.03 |
| Gross Margin | 29.8% | 29.8% | 31.7% | 42.0% | 45.0% |
| Operating Margin | -4.3% | -4.3% | 2.7% | 1.5% | 7.5% |
| Net Margin | -4.2% | -4.2% | 2.4% | 2.3% | 5.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | 0.11 | 0.10 | 0.10 |
| Current Ratio | 2.01 | 2.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $125.0M | $125.0M | $2.2M | $38.3M | $41.5M |
| Returns | |||||
| ROE | -6.3% | -6.3% | 2.7% | 2.7% | 6.1% |
| Valuation | |||||
| P/E | — | — | 10.74 | 11.39 | 5.34 |
| EV/EBITDA | — | — | 1.31 | -0.10 | 0.74 |
| P/B | 0.28 | 0.28 | 0.29 | 0.30 | 0.33 |
| Growth & Yield | |||||
| Revenue Growth | -6.7% | -6.7% | -2.2% | 7.9% | — |
| EPS Growth | — | — | 3.5% | -55.6% | — |
| Dividend Yield | 4.2% | 4.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → n/d
Residual
-34.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.